Targeting the EphB4 receptor tyrosine kinase sensitizes HER2-positive breast cancer cells to Lapatinib-Reference-Cited by-同舟云学术

Targeting the EphB4 receptor tyrosine kinase sensitizes HER2-positive breast cancer cells to Lapatinib

Published:2020-04 Issue: Volume:475 Page:53-64
ISSN:0304-3835
Container-title:Cancer Letters
language:en
Short-container-title:Cancer Letters

Author:

Ding Jinlei,Yao Yating,Huang Gena,Wang Xiaonan,Yi Jingyan,Zhang Nan,Liu Chongya,Wang Kainan,Zhang Yuan,Wang Min,Liu Pixu,Ye Mingliang,Li Man,Cheng Hailing

Funder

National Natural Science Foundation of China

National Key R&D Program of China

Liaoning Provincial Climbing Scholars Supporting Program of China

Liaoning Provincial Key Basic Research Program for Colleges and Universities

Natural Science Foundation of Liaoning

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference61 articles.

1. Comprehensive molecular portraits of human breast tumours;Nature,2012

2. Treatment of HER2-positive breast cancer: current status and future perspectives;Arteaga;Nat. Rev. Clin. Oncol.,2011

3. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3;Baselga;Nat. Rev. Canc.,2009

4. Mechanisms of trastuzumab resistance and their clinical implications;Lan;Ann. N. Y. Acad. Sci.,2005

5. Circumventing de novo and acquired resistance to trastuzumab: new hope for the care of ErbB2-positive breast cancer;Piccart;Clin. Breast Canc.,2008

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeted dual degradation of HER2 and EGFR obliterates oncogenic signaling, overcomes therapy resistance, and inhibits metastatic lesions in HER2-positive breast cancer models;Drug Resistance Updates;2024-05

2. Development of an Anti-EphB4 Monoclonal Antibody for Multiple Applications Against Breast Cancers;Monoclonal Antibodies in Immunodiagnosis and Immunotherapy;2023-10-01

3. Preclinical and Basic Research Strategies for Overcoming Resistance to Targeted Therapies in HER2-Positive Breast Cancer;Cancers;2023-04-30

4. Signals transduced by Eph receptors and ephrin ligands converge on MAP kinase and AKT pathways in human cancers;Cellular Signalling;2023-04

5. Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective;Signal Transduction and Targeted Therapy;2022-09-17